Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANTICANCER INC. PLANNING CLINICAL TRIALS AT THREE SOVIET HOSPITALS

Executive Summary

ANTICANCER INC. PLANNING CLINICAL TRIALS AT THREE SOVIET HOSPITALS under recent agreements with the institutions. The San Diego contract testing firm plans to enter into additional individual contracts with U.S. drug companies to carry out clinical testing of anticancer drugs in the Soviet Union. The firm has not yet reached any agreements with drug firms, but AntiCancer President Robert Hoffman says trials "could begin in the next few months." The three hospitals, all located in Moscow, are the All Union Cancer Research Center, the All Union Scientific Center for Hematology and the Herzen Moscow Cancer Research Institute. Hoffman said the Soviet hospitals are "centralized institutions with large patient populations" that offer the opportunity to conduct a clinical trial with a large population "under standard uniform conditions." Under the agreement with the hospitals, AntiCancer will have access to patient records. AntiCancer Inc. was founded three years ago by Hoffman and Hara Stuthas, both from the University of California at San Diego, where Hoffman is a professor. Hoffman said AntiCancer has conducted preclinical trials for five major pharmaceutical companies. The privately-held company will first conduct preclinical trials of a drug in the U.S. before offering to do clinicals in the Soviet Union. Hoffman began collaborating with scientists in the Soviet Union 15 years ago, as a participant in the National Academy of Sciences scientist exchange program. AntiCancer Inc. has obtained four Small Business Innovation Research (SBIR) grants from the National Cancer Institute in the last two years. The grants were for development of technology for drug development and evaluation and for the development of DNA probes for the diagnosis of colon cancer and pre-malignancy.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS016096

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel